The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
The emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767
Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase
Simoncini, T., Hafezi-Moghadam, A., Brazil, D. P., Ley, K., Chin, W. W., & Liao, J. K. (2000) · Nature · doi:10.1038/35035131 · Cited by 1,436
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.035 · Cited by 1,174
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 968
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer
Campbell, I. G., Russell, S. E., Choong, D. Y. H., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. F., Cristiano, B. E., Pearson, R. B., & Phillips, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2933 · Cited by 916
Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., Mansukhani, M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 875
Hennessy, B. T., Gonzalez-Angulo, A.-M., Stemke-Hale, K., Gilcrease, M. Z., Krishnamurthy, S., Lee, J.-S., Fridlyand, J., Sahin, A., Agarwal, R., Joy, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3441 · Cited by 874
Cyclin D-dependent kinases, INK4 inhibitors and cancer
Ortega, S., Malumbres, M., & Barbacid, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00037-9 · Cited by 778
Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703
Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S. H., Zhang, J., Signoretti, S., Loda, M., Roberts, T. M., et al. (2008) · Nature · doi:10.1038/nature07091 · Cited by 688
Ellis, M. J., Tao, Y., Luo, J., A'Hern, R., Evans, D. B., Bhatnagar, A. S., Chaudri Ross, H. A., von Kameke, A., Miller, W. R., Smith, I., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn309 · Cited by 653
Baselga, J., Semiglazov, V., van Dam, P., Manikhas, A., Bellet, M., Mayordomo, J., Campone, M., Kubista, E., Greil, R., Bianchi, G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8391 · Cited by 636
Anderson, W. F., Chatterjee, N., Ershler, W. B., & Brawley, O. W. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1020299707510 · Cited by 585
Miller, T. W., Hennessy, B. T., González-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., García-Echeverría, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 551
Saal, L. H., Johansson, P., Holm, K., Gruvberger-Saal, S. K., She, Q.-B., Maurer, M., Koujak, S., Ferrando, A. A., Malmström, P., Memeo, L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702507104 · Cited by 520
Gutierrez, M. C., Detre, S., Johnston, S., Mohsin, S. K., Shou, J., Allred, D. C., Schiff, R., Osborne, C. K., & Dowsett, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.172 · Cited by 489
O'Donnell, A., Faivre, S., Burris, H. A., Rea, D., Papadimitrakopoulou, V., Shand, N., Lane, H. A., Hazell, K., Zoellner, U., Kovarik, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0988 · Cited by 479
Davies, B. R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.-H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0824-t · Cited by 471
Miller, T. W., Rexer, B. N., Garrett, J. T., & Arteaga, C. L. (2011) · Breast Cancer Research · doi:10.1186/bcr3039 · Cited by 462
Gewinner, C., Wang, Z. C., Richardson, A., Teruya-Feldstein, J., Etemadmoghadam, D., Bowtell, D., Barretina, J., Lin, W. M., Rameh, L., Salmena, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.006 · Cited by 461
Viale, G., Regan, M. M., Maiorano, E., Mastropasqua, M. G., Dell'Orto, P., Rasmussen, B. B., Raffoul, J., Neven, P., Orosz, Z., Braye, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9453 · Cited by 452
Dowsett, M., Allred, C., Knox, J., Quinn, E., Salter, J., Wale, C., Cuzick, J., Houghton, J., Williams, N., Mallon, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9437 · Cited by 450
Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
Miller, T. W., Balko, J. M., & Arteaga, C. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4879 · Cited by 413
Law, J. H., Habibi, G., Hu, K., Masoudi, H., Wang, M. Y. C., Stratford, A. L., Park, E., Gee, J. M. W., Finlay, P., Jones, H. E., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2755 · Cited by 401
PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
Kalinsky, K., Jacks, L. M., Heguy, A., Patil, S., Drobnjak, M., Bhanot, U. K., Hedvat, C. V., Traina, T. A., Solit, D., Gerald, W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0632 · Cited by 401
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
Rader, J., Russell, M. R., Hart, L. S., Nakazawa, M. S., Belcastro, L. T., Martinez, D., Li, Y., Carpenter, E. L., Attiyeh, E. F., Diskin, S. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1675 · Cited by 394
Perren, A., Weng, L.-P., Boag, A. H., Ziebold, U., Thakore, K., Dahia, P. L. M., Komminoth, P., Lees, J. A., Mulligan, L. M., Mutter, G. L., et al. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65227-3 · Cited by 378
Loi, S., Haibe-Kains, B., Majjaj, S., Lallemand, F., Durbecq, V., Larsimont, D., Gonzalez-Angulo, A. M., Pusztai, L., Symmans, W. F., Bardelli, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907011107 · Cited by 356
Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
Markman, B., Dienstmann, R., & Tabernero, J. (2010) · Oncotarget · doi:10.18632/oncotarget.188 · Cited by 355
De Laurentiis, M., Arpino, G., Massarelli, E., Ruggiero, A., Carlomagno, C., Ciardiello, F., Tortora, G., D'Agostino, D., Caputo, F., Cancello, G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2569 · Cited by 340
Johnston, S. R. D., Saccani‐Jotti, G., Smith, I. E., Salter, J., Newby, J. C., Coppen, M. J., Ebbs, S. R., & Dowsett, M. (1995) · PubMed · Cited by 301
Pérez-Tenorio, G., Alkhori, L., Olsson, B., Waltersson, M. A., Nordenskjöld, B., Rutqvist, L. E., Skoog, L., & Stål, O. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1609 · Cited by 292
Fedele, C. G., Ooms, L. M., Ho, M., Vieusseux, J., O'Toole, S. A., Millar, E. K., Lopez-Knowles, E., Sriratana, A., Gurung, R., Baglietto, L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015245107 · Cited by 283
Mita, M. M., Mita, A. C., Chu, Q. S., Rowinsky, E. K., Fetterly, G. J., Goldston, M., Patnaik, A., Mathews, L., Ricart, A. D., Mays, T., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0345 · Cited by 273
Wolff, A. C., Lazar, A. A., Bondarenko, I., Garin, A. M., Brincat, S., Chow, L., Sun, Y., Neskovic-Konstantinovic, Z., Guimaraes, R. C., Fumoleau, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3331 · Cited by 272
Raynaud, F. I., Eccles, S. A., Patel, S., Alix, S., Box, G., Chuckowree, I., Folkes, A., Gowan, S., De Haven Brandon, A., Di Stefano, F., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1200 · Cited by 271
Creighton, C. J., Fu, X., Hennessy, B. T., Casa, A. J., Zhang, Y., Gonzalez-Angulo, A. M., Lluch, A., Gray, J. W., Brown, P. H., Hilsenbeck, S. G., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2594 · Cited by 258
Ellard, S. L., Clemons, M., Gelmon, K. A., Norris, B., Kennecke, H., Chia, S., Pritchard, K., Eisen, A., Vandenberg, T., Taylor, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3033 · Cited by 258
Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy
Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs002 · Cited by 255
O'Brien, C., Wallin, J. J., Sampath, D., GuhaThakurta, D., Savage, H., Punnoose, E. A., Guan, J., Berry, L., Prior, W. W., Amler, L. C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2828 · Cited by 255
S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation
Yamnik, R. L., Digilova, A., Davis, D. C., Brodt, Z. N., Murphy, C. J., & Holz, M. K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807532200 · Cited by 246
New Strategies in Estrogen Receptor–Positive Breast Cancer
Johnston, S. R. D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1823 · Cited by 230
Sutherlin, D. P., Bao, L., Berry, M., Castanedo, G., Chuckowree, I., Dotson, J., Folks, A., Friedman, L., Goldsmith, R., Gunzner, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2009327 · Cited by 219
PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Stemke-Hale, K., Sahin, A., Liu, S., Barrera, J. A., Burgues, O., Lluch, A. M., Chen, H., Hortobagyi, G. N., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1089 · Cited by 219
Crowder, R. J., Phommaly, C., Tao, Y., Hoog, J., Luo, J., Perou, C. M., Parker, J. S., Miller, M. A., Huntsman, D. G., Lin, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4450 · Cited by 218
PIK3CA mutations in breast cancer are associated with poor outcome
Li, S. Y., Rong, M., Grieu, F., & Iacopetta, B. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9048-0 · Cited by 207
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen
Encarnaci�n, C. A., Ciocca, D. R., McGuire, W. L., Clark, G. M., Fuqua, S. A. W., & Osborne, C. K. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00665801 · Cited by 194
Sanchez, C. G., Ma, C. X., Crowder, R. J., Guintoli, T., Phommaly, C., Gao, F., Lin, L., & Ellis, M. J. (2011) · Breast Cancer Research · doi:10.1186/bcr2833 · Cited by 184
Ndubaku, C. O., Heffron, T. P., Staben, S. T., Baumgardner, M., Blaquiere, N., Bradley, E., Bull, R., Do, S., Dotson, J., Dudley, D., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4003632 · Cited by 179
Ellis, M. J., Tao, Y., Young, O., White, S., Proia, A. D., Murray, J., Renshaw, L., Faratian, D., Thomas, J., Dowsett, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3034 · Cited by 173
Zhang, Y., Moerkens, M., Ramaiahgari, S., de Bont, H., Price, L., Meerman, J., & van de Water, B. (2011) · Breast Cancer Research · doi:10.1186/bcr2883 · Cited by 171
Miller, T. W., Pérez-Torres, M., Narasanna, A., Guix, M., Stål, O., Pérez-Tenorio, G., Gonzalez-Angulo, A. M., Hennessy, B. T., Mills, G. B., Kennedy, J. P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0042 · Cited by 168
Dixon, J. M., Renshaw, L., Young, O., Murray, J., Macaskill, E. J., McHugh, M., Folkerd, E., Cameron, D. A., A'Hern, R. P., & Dowsett, M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9279 · Cited by 160
Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women
Maruyama, N., Miyoshi, Y., Taguchi, T., Tamaki, Y., Monden, M., & Noguchi, S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0267 · Cited by 152
Maurer, M. S., Su, T., Saal, L. H., Koujak, S., Hopkins, B. D., Barkley, C. R., Wu, J., Nandula, S. V., Dutta, B., Xie, Y., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0820 · Cited by 143
Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen
Shoman, N. M., Klassen, S., McFadden, A., Bickis, M., Torlakovic, E., & Chibbar, R. (2004) · Modern Pathology · doi:10.1038/modpathol.3800296 · Cited by 142
Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels
Geisler, J., Helle, H., Ekse, D., Duong, N. K., Evans, D. B., Nordbø, Y., Aas, T., & Lønning, P. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5221 · Cited by 140
Ellis, M. J., Li, L., Crowder, R. J., Yu, T., Hoog, J., Snider, J., Davies, S. R., DeSchryver, K., Evans, D. B., Steinseifer, J., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0575-y · Cited by 130
Finn, R., Crown, J. P., Láng, I., Boér, K., Bondarenko, I., Kulyk, S. V., Ettl, J., Patel, R., Pintér, T., Schmidt, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-s1-6 · Cited by 128
O’Reilly, T., & McSheehy, P. M. J. (2010) · Translational Oncology · doi:10.1593/tlo.09277 · Cited by 128
Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype
Garcia, J. M., Silva, J. M., Domínguez, G., Gonzalez, R. M., Navarro, A., Carretero, L., Provencio, M., España, P., & Bonilla, F. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006273516976 · Cited by 122
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma
Dunlap, J. B., Le, C., Shukla, A., Patterson, J., Presnell, A., Heinrich, M. C., Corless, C. L., & Troxell, M. L. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0406-1 · Cited by 122
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women
丸山, 尚. (2009) · Cited by 119
Karlsson, E. A., Pérez‐Tenorio, G., Amin, R., Bostner, J., Skoog, L. K., Fornander, T., Sgroi, D. C., Nordenskjöld, B. A., Hallbeck, A., & Stål, O. (2013) · Breast Cancer Research · doi:10.1186/bcr3557 · Cited by 112
Kim, S., Loo, A., Chopra, R., Caponigro, G., Huang, A., Vora, S., Parasuraman, S., Howard, S., Keen, N., Sellers, W., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-pr02 · Cited by 106
Bostner, J., Karlsson, E. A., Pandiyan, M. J., Westman, H., Skoog, L. K., Fornander, T., Nordenskjöld, B. A., & Stål, O. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2376-y · Cited by 102
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
Gonzalez-Angulo, A. M., & Blumenschein, G. R. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.11.002 · Cited by 101
Deforolimus trial 106- A Phase I trial evaluating 7 regimens of oral Deforolimus (AP23573, MK-8669)
Mita, M. M., Britten, C. D., Poplin, E. A., Tap, W. D., Carmona, A., Yonemoto, L., Wages, D. S., Bedrosian, C. L., Rubin, E. H., & Tolcher, A. W. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3509 · Cited by 93
Cavazzoni, A., Bonelli, M. A., Fumarola, C., Monica, S. L., Airoud, K., Bertoni, R., Alfieri, R. R., Galetti, M., Tramonti, S., Galvani, E., et al. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.034 · Cited by 88
Dysregulated PTEN‐PKB and negative receptor status in human breast cancer
Shi, W., Zhang, X., Pintilie, M., Ma, N., Miller, N. A., Banerjee, D., Tsao, M., Mak, T. W., Fyles, A., & Liu, F. (2003) · International Journal of Cancer · doi:10.1002/ijc.10909 · Cited by 87
A 2009 Update on the Treatment of Patients with Hormone Receptor—Positive Breast Cancer
Cleator, S. J., Ahamed, E., Coombes, R. C., & Palmieri, C. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.s.001 · Cited by 82
Meric‐Bernstam, F., Chen, H., Akçakanat, A., Do, K.-A., Lluch, A. M., Hennessy, B. T., Hortobágyi, G. N., Mills, G. B., & Gonzalez-Angulo, A. M. (2012) · Breast Cancer Research · doi:10.1186/bcr3343 · Cited by 80
Wagner, A. J., Bendell, J. C., Dolly, S. O., Morgan, J. A., Ware, J. A., Fredrickson, J. O., Mazina, K. E., Lauchle, J., Burris, H. A., & Bono, J. S. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3020 · Cited by 73
Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer
Pérez‐Tenorio, G., Karlsson, E. A., Waltersson, M. A., Olsson, B., Holmlund, B., Nordenskjöld, B. A., Fornander, T., Skoog, L. K., & Stål, O. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1058-x · Cited by 71
Beelen, K. J., Opdam, M., Severson, T., Koornstra, R. H. T., Vincent, A. D., Wesseling, J., Muris, J. J. F., Berns, E. M. J. J., Vermorken, J. B., van Diest, P. J., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3606 · Cited by 66
Baselga, J. M., Cortés, J., Im, S., Clark, E., Kiermaier, A. C., Ross, G., & Swain, S. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-s5-1 · Cited by 58
Kalinsky, K. M., Heguy, A., Bhanot, U. K., Patil, S. N., & Moynahan, M. E. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1601-4 · Cited by 57
Generali, D., Fox, S. B., Brizzi, M. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1046 · Cited by 55
Elevated PI3K signaling drives multiple Breast Cancer subtypes
Adams, J. R., Schachter, N. F., Liu, J. C., Zacksenhaus, E., & Egan, S. E. (2011) · Oncotarget · doi:10.18632/oncotarget.285 · Cited by 53
Gonzalez-Angulo, A. M., Juric, D., Argilés, G., Schellens, J. H. M., Burris, H. A., Berlin, J. D., Middleton, M. R., Schüler, M., van Geel, R. M. J. M., Helgason, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2531 · Cited by 52
Beelen, K. J., Opdam, M., Severson, T., Koornstra, R. H. T., Vincent, A. D., Wesseling, J., Muris, J. J. F., Berns, E. M. J. J., Vermorken, J. B., van Diest, P. J., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3598 · Cited by 48
New therapeutic approaches in breast cancer
Davies, E. L., & Hiscox, S. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.10.012 · Cited by 46
Juric, D., Krop, I. E., Ramanathan, R. K., Xiao, J. J., Sanabria, S., Wilson, T. R., Choi, Y., Parmar, H. R., Hsu, J. Y., Baselga, J. M., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-lb-64 · Cited by 43
Fu, P., Ibusuki, M., Yamamoto, Y., Hayashi, M., Murakami, K., Zheng, S., & Iwase, H. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1605-0 · Cited by 41
Voliva, C. F., Pecchi, S., Burger, M. T., Nagel, T., Schnell, C., Fritsch, C. M., Brachmann, S. M., Menezes, D. L. D., Knapp, M. S., Shoemaker, K. R., et al. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-4498 · Cited by 32
Tan, D. S.-W., Lim, K. H., Tai, W. M. D., Ahmad, A., Pan, S., Ng, Q. S., Ang, M., Gogna, A., Ng, Y. L., Tan, B. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8107 · Cited by 30
The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy
Cosimo, S. D., Scaltriti, M., del Val, D. J., Rojo, F., Guzmán, M., Jimenez, J., Seoane, J., Arribas, J., & Baselga, J. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3511 · Cited by 22
Piccart, M. J., Baselga, J. M., Noguchi, S., Burris, H. A., Gnant, M., Hortobágyi, G. N., Mukhopadhyay, P., Taran, T., Sahmoud, T., & Rugo, H. S. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-p6-04-02 · Cited by 19
BOLERO-2: Efficacy and safety of first-line everolimus plus exemestane in advanced breast cancer.
Rugo, H. S., Campone, M., Gnant, M., Neven, P., Pistilli, B., Baselga, J. M., Bauly, H., Taran, T., Sahmoud, T., & Hortobágyi, G. N. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.26_suppl.152 · Cited by 5
Cited by
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Yu, L., Wei, J., & Liu, P. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 763
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 613
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Wang, J., & Xu, B. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0069-2 · Cited by 393
Animal models and therapeutic molecular targets of cancer: utility and limitations
Cekanova, M., & Rathore, K. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s49584 · Cited by 274
Kondo, H., Ratcliffe, C. D. H., Hooper, S., Ellis, J., MacRae, J. I., Hennequart, M., Dunsby, C. W., Anderson, K. I., & Sahai, E. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108750 · Cited by 109
Metadata
- Authors
- Ciruelos Gil, E. M.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 40
- Issue
- 7
- Pages
- 862-871
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2016450639
- Cited by
- 314
- References
- 103
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.